Clinical Trial

Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke

Study acronym: TREND-2
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated October 29, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
A prospective, multicenter, randomized, controlled, open-label, blinded endpoint trial to evaluate the safety and efficacy of intravenous administration of tirofiban for preventing early neurological deterioration after intravenous thrombolysis in patients with acute ischemic stroke.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-05; most recent amendment 2024-10-28.
Trial Details
NCT Number NCT06587347
Lead Sponsor Capital Medical University
Conditions Acute Stroke, Ischemic Stroke, Acute, Cerebral Infarction
Enrollment 302 participants
Start Date 2024-11-20
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-29